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A B S T R A C T
The purpose of this study was to prepare the oleanolic acid–phospholipid complex (OA-
PC) and then solidify it employing fumed silica by simple solvent evaporation technique
to improve dissolution rate of oleanolic acid and oleanolic acid–phospholipid complex. The
process of OA-PC was optimized and the type and proportion of fumed silica were studied
by dissolution text. The structures of the phospholipid complex and solidified powder were
also characterized by differential scanning calorimetry, X-ray diffraction, and scanning elec-
tron microscope. In the dissolution tests, OA from solidified powder was further released
compared with that from pure OA and OA-PC in different kinds of dissolution media. These
results suggest that the method of preparing solidified powder of oleanolic acid–phospholipid
complex is suitable for enhancing the dissolution rate of OA and OA-PC.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical
University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Oleanolic acid, 3β-3-hydroxyolean-12-en-28-oic acid (OA, Fig. 1),
is a triterpenoid compound that exists widely in many Asian
herbs, such as Fructus ligustri lucidi, Fructus orsythiae, and
Akebia trifoliate. OA has multiple pharmaceutical functions such
as anti-inflammatory, enhancement of human body defense
systems and hypoglycemic [1]. In clinical, OA is available over
the counter in tablet form and has been used for several decades
as an adjunct therapy for hepatitis [2]. However, OA is a class
IV drug according to the Biopharmaceutics Classification System
[3], and has an absolute oral bioavailability of only 0.7% because
of its low permeability (Papp = 1.1 − 1.3 × 10 − 6 cm/s in the apical-
to-basolateral direction at 10 and 20 μM) [4] and low aqueous
solubility (<1 μg/ml) [5] . This has restricted the use of variet-
ies of pharmacological activities of OA for treating different
disorders.
Several techniques had been attempted to improve the dis-
solution of OA, for example, preparation of different crystal
forms of OA by recrystallization [5], preparing solid disper-
sion [6], nanoemulsions [7] and nanosuspensions [8]. However,
solid dispersion and nanosuspensions focused on the disso-
lution improvement of OA and paid no attention to the poor
permeability of oleanolic acid, another potential root-cause of
low bioavailability. In the case of nanoemulsions, the complex
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technology and large amount of excipients added were a large
challenge.Thus, the proper formulation of oleanolic acid should
improve not only solubility and dissolution but also mem-
brane permeability of OA. Recently, the drug–phospholipid
complex technique is demonstrated as a promising method
to improve membrane permeability and water solubility, thereby
enhancing bioavailability for BCSIV drugs [9–12].
Phospholipids are an important component of the cell mem-
brane which can penetrate the cell membrane easily. Besides,
it also treats hepatic disorder. Today, phospholipids are widely
used as active ingredients and pharmaceutical excipients. The
drug–phospholipid complex can improve membrane penetra-
tion potential and absorption of drugs, which enhance the
bioavailability of BCSIV drugs [13,14].
However, the drug–phospholipid complex also has large
stickiness, which would pose a challenge for drug dissolu-
tion, further processing into other formulations and industrial
production. Thus, appropriate carriers might be employed to
solidify the drug–phospholipid complex in order to lower sticki-
ness of OA-PC. Fumed silica has a high specific surface area
and porosity, strong adsorption ability and good wetting prop-
erties, and it is usually used as a carrier to improve dissolution
of poorly soluble drugs [15,16]. Consequently, we studied the
effects of different types of fumed silica on dissolution of OA.
In the present studies, novel solidified powder of the
oleanolic acid–phospholipid complex was first prepared using
solvent evaporation method based on the OA-PC. The pre-
pared OA-PC and solidified powder were evaluated by thermal
behavior (DSC), X-ray diffraction (XRD) and scanning electron
microscope (SEM). Moreover, dissolution profiles of the novel
solidified powders were compared with pure OA and OA-PC.
2. Materials and methods
2.1. Materials
OA (purity of 98.0%) was purchased from Shikun Sichuan Phar-
maceutical Co. Ltd. Lipoid E200 (trade name of phospholipid,
purity 80%) was purchased from Shanghai Advanced Vehicle
Technology Co. Ltd. Fumed Silica (EY-QX1) was purchased from
Shanhe Anhui Pharmaceutical Co. Ltd. Fumed Silica (CAB-O-
SIL M-5, USA; AEROSIL 380, USA) was supplied by Beijing Fengli
Jingqiu Commerce and Trade Co. Ltd. Methanol (chromato-
graphic grade) was purchased from Kangkede Tianjin Co. Ltd
(China). Phosphate (chromatographic grade) was supplied by
Kemio Tianjin Co. Ltd (China).The other chemical reagents were
of analytical grade or better.
2.2. Preparation of the OA-PC and solidified powders by
solvent-evaporation method
2.2.1. Screening the best molar proportion of phospholipids
and drug
The drug and phospholipid at the molar ratios of 1:0.5, 1:1, 1:2
and 1:3 were accurately taken into a 100 ml round bottom flask
and 20 ml anhydrous ethanol was added then refluxed at 60 °C
for 2 h. The anhydrous ethanol was removed by rotary evapo-
rator at 40 °C. The dried residues were gathered and dried in
desiccators overnight, and then sieved with an 80 mesh. To
obtain the optimal molar ratio of OA to phospholipid, the solu-
bility of the drugs in phospholipid complexes was determined
using HPLC method. According to the results of the solubility
assay, the optimum molar ratio of OA and phospholipid was
determined.
2.2.2. Screening the best reaction temperature of
phospholipids and drug
The drug and phospholipid at the molar ratio of 1:1 were taken
into a 100 ml round bottom flask and dissolved in anhydrous
ethanol. The mixture was refluxed under 30, 40, 60 and 80 °C
for 2 h, respectively. Then the anhydrous ethanol was removed
by rotary evaporator at 40 °C. The dried residues were placed
in desiccators overnight, then sieved with an 80 mesh and
stored at room temperature. To choose the best reaction tem-
perature, the water solubility of OA in prepared OA-PC complex
was determined using HPLC method. Based on the results of
the solubility study, we determine the best reaction tempera-
ture of phospholipids and drug.
2.2.3. Screening the best reaction time of phospholipids and
drug
The drug and phospholipid at the molar ratio of 1:1 were taken
into a 100 ml round bottom flask and dissolved in anhydrous
ethanol. The mixture was refluxed under 60 °C for 0.5, 1, 1.5,
2, 3 h respectively. Then the anhydrous ethanol was removed
by rotary evaporator at 40 °C. The dried residues were placed
in desiccators overnight, then sieved with an 80 mesh and
stored at room temperature. Then the solubility of prepared
OA-PC complex was studied and the best reaction time of phos-
pholipids and drug was determined.
2.2.4. Screening the kinds of fumed silica
The drug and phospholipid at the molar ratio of 1:1 (account
to 1:2, w/w) were taken into a 100 ml round bottom flask and
dissolved in anhydrous ethanol.The mixture was refluxed under
60 °C for 2 h. Then same amount of different kinds of fumed
silica (CAB-O-SIL M-5, AEROSIL 380 and EY-QX1) was added into
the above solution and constantly stirred for a period of time.
Then the anhydrous ethanol was removed by rotary evapora-
tor at 40 °C. The dried residues were placed in desiccators
overnight, then sieved with an 80 mesh and stored at room
temperature. According to the results of the dissolution test,
the favorable kinds of fumed silica were determined.
2.2.5. Screening the optimal proportion of OA and fumed
silica
The drug and phospholipid at the molar ratio of 1:1 (account
to 1:2, w/w) were taken into a 100 ml round bottom flask and
Fig. 1 – The chemical structures of OA.
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dissolved in anhydrous ethanol.The mixture was refluxed under
60 °C for 2 h. Then fumed silica in different mass ratios (OA:
fumed silica =1:3; 1:5; 1:7; 1:9) were added into the above so-
lution respectively, and constantly stirred for a period of time.
Then the anhydrous ethanol was removed by rotary evapora-
tor at 40 °C. The dried residues were placed in desiccators
overnight, then sieved with an 80 mesh and stored at room
temperature. Based on the dissolution results, we were able
to determine the optimal proportion of OA and fumed silica.
2.3. Differential scanning calorimetric analysis (DSC)
DSC curves were carried out with a Mettler DSC 30S (Mettler
Toledo, Switzerland). The samples including pure OA, phos-
pholipid, OA-PC, fumed silica, physical mixture of OA, PC, and
fumed silica and solidified powder were sealed into alumi-
num pans separately and heated from 40 to 350 °C, at a heating
rate of 10 °C/min.
2.4. X-ray diffraction (XRD)
The crystalline state of pure OA, phospholipid, OA-PC, fumed
silica, physical mixture and solidified powder were measured
at room temperature on D/max-r A (Rigaku Denki, Japan)
equipped with a Cu Ka radiation source at 45 kV and 30 mA.
The text was carried out from 2° to 50° in the range of 2θ.
2.5. Scanning electron microscopy (SEM)
SEM (SU 8000, Hitachi, Japan) was employed to observe the mor-
phology of pure OA, phospholipid, OA-PC, fumed silica, physical
mixture and solidified powder In brief, samples were fixed on
an aluminum stub with conductive double-sided-adhesive tape
and then coated with gold. The surface morphology of the
samples was examined.
2.6. Solubility studies
Solubility determination of OA in OA-PC complex was carried
out by adding excess of the samples to 5.0 ml of water in a
sealed glass container. Each sample was performed in tripli-
cate. Then the liquids were shaken to balance in the swing bed
at 37 °C. The liquid was centrifuged at 15,000 rpm for 10 min
and the supernatant was filtered through a 0.45 μm mem-
brane. A 20 μL aliquot of the filtrate was injected into HPLC
system directly.
2.7. Dissolution profile
The dissolution tests of OA from OA-PC and solidified powder
were evaluated using the Chinese pharmacopoeia method II
(paddle method) with a ZRS-8G dissolution apparatus
(Tiandatianfa, Tianjin, China). Dissolution was conducted in
900 ml different concentrations of sodium dodecyl sulfate (SDS)
aqueous solution to satisfy the sink conditions. We chose 0.3%
sodium dodecyl sulfate (SDS) aqueous solution as the disso-
lution medium to determine the optimal solidified carrier and
its proportion in powders.The paddle speed was set to 100 rpm
and the water bath temperature was maintained at 37 ± 0.5 °C.
OA, OA-PC and solidified powders which were equivalent to
20 mg OA were added to the dissolution medium. The disso-
lution medium of 5 ml was withdrawn after 5, 10, 20, 30, 45,
60, 90 and 120 min, and replaced with the same medium
volume. The withdrawn samples were filtrated (0.45 μm) and
analyzed by HPLC at 210 nm.
2.8. HPLC analysis
All the involved samples were analyzed by HPLC (Shimadzu,
Japan) on a C18 column (Thermo C18, 4.6 × 150 mm, 5 μm, USA)
and the column was kept at room temperature. The mobile
phase was methanol–water–phosphate (90:10:0.01 v/v/v) and
the flow rate was 1.0 ml/min. The wavelength of the UV de-
tector was set at 210 nm.
3. Results and discussion
3.1. The best molar ratio of OA to phospholipid
According to the article, the process of phospholipid complex
is usually evaluated by the combination ratio of drug and phos-
pholipids [17]. However, in this study, OA has a good lipophilicity
and it is difficult to find a suitable solvent to calculate the com-
bination ratio of OA and phospholipid. Thus, the variation of
solubility of OA-PC was chosen to evaluate the process of phos-
pholipid complex. In Fig. 2 we can see that, under the same
reaction temperature and time, the solubility of OPC is im-
proved with the increased proportion of phospholipids in
complex. Considering that the variation of solubility among
the molar ratios of 1:1, 1:2 and 1:3 was not very distinguished,
the optimal molar ratio of drug to phospholipid was selected
at 1:1.
3.2. The best reaction temperature of phospholipids and
drug
Based on the results presented in Fig. 3, the solubility of OA-
PC was increased with the variation of reaction temperature
from 30 to 60 °C, which showed that the formation of phos-
pholipid complex could be positively correlated with reaction
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Fig. 2 – The solubility of OA in OA-PC at different molar
ratios of OA to phospholipid.
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temperature. When the temperature was increased to 80 °C,
solubility of OA-PC reduced. This might be explained by the
oxidation of phospholipid due to high temperature .Thus, 60 °C
was chosen as the optimal reaction temperature in this study.
3.3. The best reaction time of phospholipids and drug
Fig. 4 shows that the solubility of OA-PC was enhanced with
the increase in reaction time from 0.5 to 2 h. However, after
2 h reaction was done, the solubility of OPC was not in-
creased with the variation of time. As a result, the reaction time
of 2 h is most appropriate in the process of phospholipid
complex.
3.4. The best kinds of fumed silica
To improve the poor flowability and dissolution of OA-PC, we
further prepared the solidified powders of OA-PC employing
different kinds of fumed silica including CAB-O-SIL M-5 (spe-
cific surface area 200 ± 25 m2/g, and particles 12 nm), AEROSIL
380 (specific surface area 380 ± 30 m2/g, and particles 7 nm) and
EY-QX1 (particles 15 nm). As shown in Fig. 5, the properties of
the solidified carriers played an important role in the disso-
lution profile of the drug. These kinds of solidified powders
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Fig. 3 – The solubility of OA in OA-PC at different reaction
temperatures.
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Fig. 4 – The solubility of OA in OA-PC at different reaction
times.
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Fig. 5 – The dissolution profiles of the OA-PC-solidified
powders prepared by different types of fumed silica in 0.3%
SDS aqueous solution.
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Fig. 6 – The dissolution profiles of the solidified powders
with different mass ratios of OA to fumed silica in 0.3%
SDS aqueous solution.
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Fig. 7 – DSC spectra of (A) OA, (B) phospholipid, (C) OA-PC,
(D) fumed silica, (E) physical mixture, and (F) solidified
powder.
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exhibited higher dissolution rate compared with the pure OA
and OA-PC. Furthermore, due to the higher specific surface area
and lower particle size, the solidified powder using AEROSIL
380 as solidified carrier displayed higher dissolution com-
pared with the other kinds of solidified powders.
3.5. The best proportion of OA and fumed silica
The best proportion of fumed silica in solidified powders was
studied by dissolution test and the results were shown in Fig. 6.
From the figure, we can see that the solidified powders of OA-
PC with mass ratio of OA to fumed silica of 1:7 exhibited the
highest dissolution rate. When fumed silica increased, disso-
lution rates were not improved. Consequently, the mass ratio
of OA to fumed silica of 1:7 was the best.
3.6. DSC
DSC study is an important method to reveal compatibility
between drugs and excipients and provides large information
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Fig. 8 – X-ray diffractograms of (A) OA, (B) phospholipid,
(C) OA-PC, (D) fumed silica, (E) physical mixture, and
(F) solidified powder.
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Fig. 9 – SEM images of (A) OA, (B) phospholipid, (C) OA-PC, (D) fumed silica, (E) physical mixture, and (F) solidified powder.
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about possible interactions [18]. Fig. 7 shows the DSC thermo-
grams of original OA (A), phospholipid (B), OA-PC (C), fumed
silica (D), physical mixture of OA, phospholipid and fumed silica
(E) and solidified powder (F). An endothermic peak was found
at 312 °C for the crude OA and physical mixture, indicative of
its anhydrous and crystalline state. On the contrary, both in
the OA-PC and solidified powders, the endothermic peak of OA
substance disappeared, indicating the amorphous form of OA
in OA-PC and solidified powders.
3.7. XRD
Fig. 8 displays the X-ray diffraction patterns of original OA (A),
phospholipid (B), OA-PC (C), fumed silica (D), physical mixture
of OA, phospholipid and fumed silica (E) and solidified powder
(F). In the X-ray diffractogram, OA material showed intense dif-
fraction peaks suggesting that the drug is present as a
crystalline material. In physical mixture, the diffraction peaks
were reduced but can still be observed easily, indicative of the
presence of a crystal form of OA. On the other hand, there were
no diffraction peaks of OA observed in OA-PC and solidified
powders, which showed that OA presents an amorphous state
in the OA-PC and solidified powders. These data support the
DSC studies which indicated the reduced crystallinity of drugs
in OA-PC and solidified powder.
3.8. SEM
As shown in Fig. 9A, the morphology of the pure OA showed
that it was in needle-like crystal. It was regular in shape and
size. Furthermore, needle-like crystals can be observed in the
physical mixture shown in Fig. 9E. From Fig. 9C and F, we can
conclude that OA showed an amorphous state in the OA-PC
and solidified powders, indicating the formation of OA-PC and
solidified powders, which was in agreement with the results
of the XRD and DSC.
3.9. Dissolution study
The dissolution profiles of original OA, OA-PC and solidified
powders in different dissolution media are plotted in Fig. 10.
Because of the viscous state of the phospholipid complex, the
dissolution of the OA-PC complex was less than crude OA.
However, the dissolution rate of the prepared solidified powder
using fumed silica as carriers was faster than that of pure OA
and OA-PC. These could be explained as follows: 1) OA was in
an amorphous state in solidified powders, which is a more
soluble form; 2) fumed silica with high specific surface area
had a good wetting and adsorption ability and was usually
served as a carrier to improve the dispersion of poorly soluble
drugs.
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Fig. 10 – Dissolution profiles of OA from crude OA, phospholipid complex (OA-PC) and solidified powders (OA-PC/silica) in
(A) 0.1% SDS aqueous solution; (B) 0.3% SDS aqueous solution; (C) 0.5 % SDS aqueous solution.
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4. Conclusions
The phospholipid complex technology can improve the
bioavailability and oral absorption of BCSIV drugs. However,
the stickiness of the phospholipid complex might limit dis-
solution of drugs and made it difficult to prepare other
formulations. In this paper, solidified powder of OA-PC was pre-
pared by a simple and feasible solvent method and it has been
proved to be able to improve the dissolution of OA and OA-
PC. Moreover, based on the solidified powder, we can further
prepare the dosage form that is easy to take and produce, which
could further develop the clinical application of OA. As a result,
solidified powder of OA-PC would be a prospective and prac-
tical drug formulation.
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